Released May 8, 2025, before the open
10-Q filed May 8, 2025, 38 days after period end · 0001171843-25-002953
Q1 2025 · 10-Q
Revenue—
Net Income-$16.63M-$16.63M N/M vs Q1 2024N/M vs Q4 2024
EPS, diluted—
Operating Income-$17,966,000N/M
Operating Cash Flow-$13,208,000N/M
Free Cash Flowderived-$13,226,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Net Income | -$16.63M | -$10.79M | -$7.84M | -$7.16M |
| EPS Diluted | — | — | — | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR